Tuesday, 9 August, 2022
HomeHealth‘Taken this up at highest levels’, Poonawalla assures India as EU Green...

‘Taken this up at highest levels’, Poonawalla assures India as EU Green Pass excludes Covishield

EU's Green Pass, which will be available for use from July 1, includes 4 vaccines approved by the European Medicines Agency.

Text Size:

New Delhi: As Europe’s new vaccine passport programme — which recognises a few Covid-19 vaccines to enable people to travel in and out of Europe with with fewer roadblocks — does not include Covishield, the AstraZeneca-Oxford vaccine manufactured in India, its manufacturer Serum Institute of India (SII) hopes to “resolve this matter soon”.

Adar Poonawalla, CEO of the Serum Institute, said he has taken this up at the “highest levels”.

“I realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries,” he said in a tweet.

 

EU’s ‘Green Pass’, which will be available for use from 1 July, will include the vaccines approved by the European Medicines Agency (EMA). To date, EMA has approved four vaccines — Comirnaty (Pfizer/BioNTech), Moderna, Vaxzervria (AstraZeneca), Janssen (Johnson & Johnson).

While it includes the AstraZeneca vaccine, it does not include Covishield. Pune-based SII hasn’t yet applied for vaccine approval by the EMA.

Green Pass to show bearer’s vaccination status

On 26 May, European Union leaders announced the introduction of “Digital Covid Certificate” — a bloc-wide Covid-19 pass, with the objective of allowing tourists.

According to reports, the EU’s Covid certificate “will show the bearer’s vaccination status, or whether they have immunity from a Covid infection they have recovered from, or the result of a Covid test.”

The certificates will have a scannable QR code to show the status of vaccination.


Also read: Blocked by Eli Lilly, Bajaj Healthcare moves patent office to make Covid drug Baricitinib


 

Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular

×